Free Trial

Abbott Laboratories (ABT) Stock Price, News & Analysis

Abbott Laboratories logo
$113.39
-1.06 (-0.93%)
(As of 10/31/2024 ET)

About Abbott Laboratories Stock (NYSE:ABT)

Key Stats

Today's Range
$113.34
$114.45
50-Day Range
$112.10
$119.39
52-Week Range
$92.43
$121.64
Volume
5.31 million shs
Average Volume
5.71 million shs
Market Capitalization
$197.29 billion
P/E Ratio
35.77
Dividend Yield
1.94%
Price Target
$129.67
Consensus Rating
Moderate Buy

Company Overview

Abbott Laboratories is a global healthcare company specializing in developing, manufacturing and marketing a wide range of healthcare products. The company has its headquarters in Abbott Park, Illinois and operates in more than 160 countries worldwide.

The company was founded in 1888 by Dr. Wallace C. Abbott, and it has since grown to become one of the world's largest and most respected healthcare companies. Abbott Laboratories has a diverse portfolio of products, including medical devices, diagnostic tests, nutritional products, and branded generic pharmaceuticals. The company is committed to developing innovative products that improve the quality of life for people worldwide.

Robert B. Ford is the current President and CEO of the company. He was appointed to this position in 2020 after serving as the company's Chief Operating Officer. He has been with Abbott Laboratories since 1996 and has held various leadership positions.

Abbott Laboratories has delivered strong financial performance, declining as investors seek growth. The company's net earnings have been increasing steadily. Abbott Laboratories has a solid balance sheet with a low debt-to-equity ratio. The company has consistently delivered strong cash flow, allowing it to invest in research and development and return value to shareholders. Abbott Laboratories has a higher price-to-earnings ratio than the industry average, and the company's price-to-book ratio is also higher than the industry average. These metrics suggest that the market has a positive outlook on Abbott Laboratories and is willing to pay a premium for the company's shares. Over the past year, Abbott Laboratories' stock has declined as consumers seek to see what the company will do post-pandemic. The company's shares have experienced some volatility, but overall, they have outperformed the broader market. 

Abbott Laboratories operates in the healthcare industry, which is highly regulated and complex. The industry is characterized by rapidly evolving technology, changing regulatory requirements, and shifting consumer preferences. Abbott Laboratories competes with other large healthcare companies such as Johnson & Johnson.

Abbott Laboratories' robust product pipeline is expected to drive growth in the coming years. The company is focused on developing innovative products that address unmet medical needs and improve patient outcomes. In addition to its core businesses, Abbott Laboratories is expanding into new markets and investing in digital health technologies.

Like any company, Abbott Laboratories faces a range of risks and challenges. One of the most significant risks facing the company is regulatory uncertainty. Changes in regulatory requirements could impact the company's ability to bring products to market and could also increase the cost of doing business. Another risk facing the company is the threat of competitive pressures. The healthcare industry is highly competitive, and Abbott Laboratories faces competition from established companies and new entrants. Changes in consumer preferences could also impact the company's performance, particularly in the nutritional products segment.

Additionally, Abbott Laboratories is exposed to geopolitical risks, such as changes in trade policies or political instability in key markets. The company's international operations also expose it to currency fluctuations, which could impact its financial performance.

Abbott Laboratories Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

ABT MarketRank™: 

Abbott Laboratories scored higher than 99% of companies evaluated by MarketBeat, and ranked 9th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Abbott Laboratories has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abbott Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Abbott Laboratories are expected to grow by 10.09% in the coming year, from $4.66 to $5.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abbott Laboratories is 35.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abbott Laboratories is 35.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.93.

  • Price to Earnings Growth Ratio

    Abbott Laboratories has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Abbott Laboratories has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abbott Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    0.81% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently increased by 18.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Abbott Laboratories pays a meaningful dividend of 1.93%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Abbott Laboratories has been increasing its dividend for 53 years.

  • Dividend Coverage

    The dividend payout ratio of Abbott Laboratories is 66.87%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 42.88% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

  • Read more about Abbott Laboratories' dividend.
  • Percentage of Shares Shorted

    0.81% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently increased by 18.17%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Abbott Laboratories has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Abbott Laboratories this week, compared to 17 articles on an average week.
  • Search Interest

    Only 68 people have searched for ABT on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • MarketBeat Follows

    46 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 15% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,495,953.00 in company stock.

  • Percentage Held by Insiders

    Only 1.10% of the stock of Abbott Laboratories is held by insiders.

  • Percentage Held by Institutions

    75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abbott Laboratories' insider trading history.
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

ABT Stock News Headlines

Abbott Laboratories logo and sign near company office in Silicon Valley. Abbott Labs is an American health care company. - Sunnyvale, California, USA , 2022 — Stock Editorial Photography
These Are The Top Health Stocks to Own for Buy-and-Hold Investing
The stocks on this list are the top three buy-and-hold stocks in healthcare, producing significant value for shareholders while leading their respective fields.
Financial markets news icon
MarketBeat Week in Review – 10/14 - 10/18 (ABT)
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Champaign - Circa June 2023: Abbott Laboratories research facility. Abbott Labs is a healthcare company that makes medical and nutrition products.
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.
Wells Fargo Sticks to Their Buy Rating for Abbott Laboratories (ABT)
See More Headlines

ABT Stock Analysis - Frequently Asked Questions

Abbott Laboratories' stock was trading at $110.07 at the beginning of the year. Since then, ABT shares have increased by 3.0% and is now trading at $113.39.
View the best growth stocks for 2024 here
.

Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, October, 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm's quarterly revenue was up 4.9% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Abbott Laboratories: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and others.

Top institutional shareholders of Abbott Laboratories include Vontobel Holding Ltd. (0.37%), Principal Financial Group Inc. (0.25%), Raymond James & Associates (0.19%) and National Pension Service (0.18%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, John F Ginascol, Andrea F Wainer, Lisa D Earnhardt, Joseph J Manning, Randel William Woodgrift, Julie L Tyler, John A Jr Mccoy, Fernando Mateus, Nancy Mckinstry, Mary K Moreland, Louis H Morrone, Sammy Karam and Michael D Dale.
View institutional ownership trends
.

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

Ex-Dividend for 8/15 Dividend
7/15/2024
Dividend Payable
8/15/2024
Ex-Dividend for 11/15 Dividend
10/15/2024
Last Earnings
10/16/2024
Today
10/31/2024
Dividend Payable
11/15/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/22/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Health Care Equipment
CUSIP
00282410
CIK
1800
Employees
114,000
Year Founded
1888

Price Target and Rating

Average Stock Price Target
$129.67
High Stock Price Target
$146.00
Low Stock Price Target
$117.00
Potential Upside/Downside
+14.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$5.72 billion
Pretax Margin
15.98%

Debt

Sales & Book Value

Annual Sales
$41.22 billion
Cash Flow
$6.19 per share
Book Value
$22.36 per share

Miscellaneous

Outstanding Shares
1,739,897,000
Free Float
1,720,758,000
Market Cap
$196.45 billion
Optionable
Optionable
Beta
0.72

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NYSE:ABT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners